Insider trading signals for ATYR over last 3 months

No results were found for insider trading activity in the past three months. However, it is important to note that lack of recent insider trading does not necessarily indicate a lack of confidence in the company. 1. **Historical Insider Transactions**: In the last twelve months, insiders have shown confidence in aTyr Pharma, with several purchases of company stock. The Independent Director, Paul Schimmel, made the largest purchase, acquiring shares worth $185k. 2. **Current Insider Ownership**: Insiders own 2.3% of aTyr Pharma shares, which is worth approximately $11m. This level of insider ownership indicates a significant alignment of interests between company leadership and smaller shareholders. 3. **Insider Transactions and Company Performance**: The completion of the Phase 3 EFZO-FIT study and the subsequent positive outcomes have led to increased investor interest and confidence in aTyr Pharma. The stock surged by 11.26% following the announcement, reflecting market optimism about the company's future prospects. In conclusion, while there may not be recent insider trading data available, the historical transactions and current insider ownership, along with the positive developments in the company's clinical trials, suggest that insiders are optimistic about aTyr Pharma's future performance.